We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

94 hedge funds and large institutions have $48.5M invested in Lineage Cell Therapeutics in 2020 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

9% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 23

3% less funds holding

Funds holding: 97 → 94 (-3)

5.45% less ownership

Funds ownership: 42.63% → 37.18% (-5.4%)

8% less capital invested

Capital invested by funds: $52.9M → $48.5M (-$4.41M)

15% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 20

Holders
94
Holders Change
-3
Holders Change %
-3.09%
% of All Funds
1.93%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
21
Increased
17
Reduced
20
Closed
23
Calls
$96K
Puts
–
Net Calls
+$96K
Net Calls Change
-$42K

Top Buyers

1
Jane Street
Jane Street
New York
+$710K
2
Russell Investments Group
Russell Investments Group
United Kingdom
+$670K
3
OMC
Old Mission Capital
Illinois
+$287K
4
PP
Paloma Partners
Connecticut
+$222K
5
DC
Defender Capital
North Carolina
+$202K

Top Sellers

1
BlackRock
BlackRock
New York
-$5.05M
2
State Street
State Street
Massachusetts
-$1.49M
3
Northern Trust
Northern Trust
Illinois
-$915K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$577K
5
N
Nuveen
North Carolina
-$350K
Name Holding Trade Value Shares
Change 		Change in
Stake
WJWM
26
Williams Jones Wealth Management
New York
$88K – – –
DCM
27
DAFNA Capital Management
California
$83K – – –
Commonwealth Equity Services
28
Commonwealth Equity Services
Massachusetts
$74K +$9.32K +10,591 +14%
Morgan Stanley
29
Morgan Stanley
New York
$73K +$23.1K +26,198 +45%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$69K -$292K -331,600 -81%
VF
31
Virtu Financial
New York
$68K +$68.7K +78,042 New
BWCS
32
Beirne Wealth Consulting Services
Connecticut
$61K +$22K +25,000 +56%
Charles Schwab
33
Charles Schwab
California
$58K -$147K -167,507 -72%
SWIG
34
Strategic Wealth Investment Group
Kentucky
$52K +$52.5K +59,597 New
State Street
35
State Street
Massachusetts
$51K -$1.49M -1,695,837 -97%
Connor, Clark & Lunn Investment Management (CC&L)
36
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$49K +$5.13K +5,823 +11%
California Public Employees Retirement System
37
California Public Employees Retirement System
California
$42K – – –
LP
38
LMR Partners
United Kingdom
$41K +$41.5K +47,157 New
SFA
39
Sequoia Financial Advisors
Ohio
$37K -$22.7K -25,814 -38%
TRCT
40
Tower Research Capital (TRC)
New York
$36K +$36.3K +41,249 New
SC
41
Scotia Capital
Ontario, Canada
$29K -$11.4K -13,000 -28%
SXL
42
Summit X LLC
Missouri
$25K -$1.5K -1,700 -6%
LPL Financial
43
LPL Financial
California
$22K +$8.82K +10,024 +64%
Victory Capital Management
44
Victory Capital Management
Texas
$21K -$22.6K -25,637 -51%
DC
45
Diametric Capital
Massachusetts
$21K +$20.7K +23,567 New
BDS
46
Banco de Sabadell
Florida
$18K – – –
RIM
47
Regent Investment Management
Kentucky
$17K – – –
MC
48
Moors & Cabot
Massachusetts
$14K -$3.52K -4,000 -20%
RJFSA
49
Raymond James Financial Services Advisors
Florida
$14K +$14.3K +16,204 New
ECM
50
Elgethun Capital Management
South Dakota
$13K – – –
1
2
3 4 5

LCTX Hedge Fund Activity: Q2 2020 in Review

94 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2020, worth a combined $48.5M — down 8.3% from $52.9M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of LCTX and 21 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 17 added.

The largest buyer was Jane Street, adding an estimated $710K. The largest seller was BlackRock, cutting an estimated $5.05M.

  • 94 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2020, down from 97 in Q1 2020.
  • Funds reported $48.5M of Lineage Cell Therapeutics stock for Q2 2020, down 8.3% quarter-over-quarter.
  • 21 funds opened new Lineage Cell Therapeutics positions in Q2 2020 and 23 closed out, a net change of -2 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2020 was Jane Street, an estimated $710K added.
  • The largest Lineage Cell Therapeutics seller in Q2 2020 was BlackRock, an estimated $5.05M sold.

Based on aggregated 13F filings for Q2 2020.